Honduras - Press Releases

TAMPA, Fla., Feb. 26, 2025 /PRNewswire/ -- The Patel Children's Heart Institute atSt. Joseph's Children's Hospitalis the first in the southeastern United States and one of only a handful of programs in the world to implant a new stent specifically created to enlarge narrowed blood vessels in the hearts of newborns and babies. The Renata Minima stent is the first and only stent small enough to be used in newborns with the capacity to be enlarged as a child grows to adulthood, reducing the need for multiple open-heart surgeries.

Middle-of-year data from Amplify shows that schools across the country have made some progress increasing the number of K-2 students on track for learning to read, but broader trends remain a concern

WASHINGTON, Feb. 26, 2025 /PRNewswire/ --The Independence Fund, a leading non-profit organization dedicated to serving the needs of wounded Veterans, Caregivers, and their families, proudly announces its endorsement of H.R. 472 - Restore VA Accountability Act of 2025 and H.R. 740 - ACCESS Act of 2025.

El lder de impacto social se centrar en impulsar la misin de Virgil Abloh de aumentar la exposicin, el acceso y las oportunidades para los jvenes creativos subrepresentados

Clients Worldwide to Benefit from Streamlined Cross-Border Money Transfers

Leap Financial and Visa, Embedded Cross Border Payments LATAM Financial Services

-Dress for Success WorldwideWomen Who Inspire

WASHINGTON, Feb. 27, 2025 /PRNewswire/ -- The U.S. Institute of Peace (USIP) is honored to announce Visaka Dharmadasaof Sri Lanka as the Fifth Annual Laureate of USIP's Women Building Peace Award.

WASHINGTON, Feb. 27, 2025 /PRNewswire/ -- The U.S. Institute of Peace (USIP) is honored to announce Visaka Dharmadasaof Sri Lanka as the Fifth Annual Laureate of USIP's Women Building Peace Award.

ZEISS VISUMAX 800 with SMILE pro software ZEISS (PRNewsfoto/Carl Zeiss Meditec)

Sold VHCIX & VENAX, Bought VFLO

ARLINGTON, Va., Feb. 26, 2025 /PRNewswire/ -- This week, the House of Representatives passeda budget resolution instructing the House Energy and Commerce Committee to cut approximately $880 billion over the next decade, with the majority of these reductions expected to come from Medicaid. These drastic cuts would severely weaken a program that provides essential healthcare to nearly 80 million people, including pregnant women, babies, and children. If enacted, these changes could lead to reduced Medicaid eligibility, fewer covered services, and new barriers to care, leaving millions without access to critical prenatal, postpartum, and infant health services. At a time when the US already faces an alarming maternal and infant health crisis, these cuts would put even more lives at risk.

MEXICO CITY, Feb. 26, 2025 /PRNewswire/ -- Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB B) ("Genomma" or "the Company"), today announced its results for the fourth quarter and full year ended December 31, 2024. All figures included herein are stated in nominal Mexican pesos and have been prepared in accordance with International Financial Reporting Standards (IFRS), unless otherwise mentioned.

LOS ANGELES, Feb. 26, 2025 /PRNewswire/ -- TheWorld Brain Mapping Foundation (WBMF) is set to make a powerful comeback. On March 1st, it will host its 22nd Annual Gathering for the Cure (GFC) award gala at the Millennium Biltmore Hotel in Los Angeles. The red carpet will take place from 6:00 to 8:00 p.m., followed by the award banquet from 8:00 to 11:00 p.m.

WUXI, China, Feb. 26, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it has again passed the GMP inspection by Japan's Pharmaceuticals and Medical Devices Agency (PMDA) for its drug substance facilities (MFG2 and MFG5), in Wuxi city.

TIANJIN, Chine, 27 fvrier 2025 /PRNewswire/ -- Le dbat sur les CSM, qui oppose les cellules stromales msenchymateuses aux cellules souches msenchymateuses, s'est poursuivi pendant prs de deux dcennies (depuis 2006), constituant l'obstacle majeur l'tude et l'application clinique des CSM. La principale question concernait les cellules souches msenchymateuses, dont l'application clinique ne peut tre approuve sans un test d'innocuit approfondi (par exemple, formation de tumeurs), mais toutes les tudes prcliniques ont prouv que les CSM actuellement prpares et utilises sont sres et ne posent pas les problmes lis aux cellules souches, tant donn qu'il s'agit bien de cellules stromales msenchymateuses, et non de cellules souches. Mais o est l'approbation ?

TIANJIN, China, 27 de febrero de 2025 /PRNewswire/ -- El debate sobre las MSC, clulas estromales mesenquimales versus clulas madre mesenquimales, ha continuado durante ms de dos dcadas (desde 2006), siendo el principal obstculo para el estudio de las MSC y su aplicacin clnica. El principal problema se centra en que las clulas madre mesenquimales no podran aprobarse para su aplicacin clnica sin una prueba exhaustiva de seguridad (por ejemplo, formacin de tumores), pero todos los estudios preclnicos demostraron que las MSC que se preparan y utilizan actualmente son seguras sin las preocupaciones relacionadas con las clulas madre, de modo que son clulas estromales mesenquimales, no clulas madre. Sin embargo, dnde est la aprobacin?

TIANJIN, China, 27. Februar 2025 /PRNewswire/ -- Die Debatte ber mesenchymale Stromazellen (MSCs) im Vergleich zu mesenchymalen Stammzellen hlt seit mehr als zwei Jahrzehnten (seit 2006) an und ist das grte Hindernis fr die Erforschung und klinische Anwendung von MSCs. Das Hauptproblem besteht darin, dass mesenchymale Stammzellen ohne eine grndliche Prfung auf Sicherheit (z.B. Tumorbildung) nicht fr die klinische Anwendung zugelassen werden knnen. Alle prklinischen Studien haben jedoch bewiesen, dass die derzeit hergestellten und verwendeten MSZ sicher sind, ohne die fr Stammzellen relevanten Bedenken, sodass es sich um mesenchymale Stromazellen und nicht um Stammzellen handelt. Doch wo bleibt die Zulassung?

TIANJIN, China, Feb. 26, 2025 /PRNewswire/ -- The debate on MSCs, mesenchymal stromal cells versus mesenchymal stem cells, continued for more than two decades (since 2006), being the major obstacle for MSCs study and clinical application. The major issue focuses on mesenchymal stem cells could not be approved for clinical application without a thorough test for safety issue (e.g. tumor formation), but all pre-clinical studies proved the MSCs currently prepared and used are safe without the concerns relevant to stem cells, so that they are mesenchymal stromal cells, not stem cells. However, where is the approval?

STOCKHOLM, Feb. 27, 2025 /PRNewswire/ -- Sobi (STO: SOBI), today announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) for Gamifant (emapalumab-Izsg) for use in adult and paediatric patients with hemophagocytic lymphohistiocytosis (HLH)/macrophage activation syndrome (MAS) in Still's disease with an inadequate response or intolerance toglucocorticoids, or with recurrent MAS.The application was granted Priority Review with a PDUFA date of June 27, 2025.

LINKPING, Sweden, Feb. 27, 2025 /PRNewswire/ -- International medical imaging IT and cybersecurity company Sectra(STO: SECT B) invites investors, analysts, and the media to a presentation of the company's nine-month report with President Torbjrn Kronander and CFO Jessica Holmquist.

Esprit at Valencia showcases beautiful new homes with open layouts and designer details

Expects to Emerge from Court-Supervised Restructuring Process In the Coming Weeks

ATLANTA, Feb. 26, 2025 /PRNewswire/ -- ECI Group (ECI) announces the sale of Houma Highlands apartments at 461 S. Hollywood Road in Houma, Louisiana to Oakwood Capital (Oakwood) for an undisclosed price. The 16-building, 378-unit community was built in phases, with Phase 1 completed in 2004 by another developer and then it was acquired by ECI and Phase II was developed and completed in 2012.

DOTHAN, Ala., Feb. 26, 2025 /PRNewswire/ -- Construction Partners, Inc. (NASDAQ: ROAD) (the "Company"), a vertically integrated civil infrastructure company specializing in the construction and maintenance of roadways in local markets throughout the Sunbelt, today announced that members of the Company's management team are scheduled to meet with investors at the Raymond James Institutional Investors Conference on March 3 and 4, 2025. The Company's "Fire Side Chat" discussion on March 3rdat 2:50 p.m. Eastern Time will be broadcast live over the internet and can be accessed via the Company's website at http://ir.constructionpartners.net/events-and-presentations.